๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› China
Clinical trial register · China

Studies with a Chinese investigative site

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the register
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University490 Fudan University472 Second Affiliated Hospital, Zhejiang University, School of Medicine404 Peking Union Medical College Hospital282 Ruijin Hospital281
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to
19052 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Comparison of Perioperative Conscious Sedation During Endovascular Thrombectomy in Acute Ischemic Stroke
NCT06139692Acute Ischemic Stroke
Jinling Hospital, China
Phase 4
810
Nanjing, Chengdu
2023-11-21
Recruiting
Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma
NCT05798793Oral Squamous Cell Carcinoma
Hospital of Stomatology, Wuhan University
Phase 3
309
Shenzhen, Wuhan, Changsha
2023-11-21
Active, closed
Guangzhou Preterm and Term Birth Cohort Study
NCT07756177Preterm Birth, Neurodevelopmental Disorders, Overweight, Obesity
Sun Yat-sen University
Observational
200
Guangzhou
2023-11-21
Recruiting
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
NCT06131840Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Pancreatic Ductal Adenocarcinoma
Seagen, a wholly owned subsidiary of Pfizer
Phase 1
914
Guangzhou, Jinan, Shanghai
2023-11-20
Recruiting
A Study of PD-1 Inhibitors Combined With Fruquintinib and Chemotherapy in First-line Treatment of HER2-negative Advanced G/GEJ Cancer
NCT06158919Gastric Cancer/Adenocarcinoma of Esophagogastric Junction
Fudan University
Not applicable
58
Shanghai
2023-11-20
Active, closed
A Phase III, Active-Controlled Study of SHR-A1811 Versus Trastuzumab Emtansine (T-DM1) in HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
NCT06126640HER2-Positive Primary Breast Cancer Participants With Residual Invasive Disease Following Neoadjuvant Therapy
Jiangsu HengRui Medicine Co., Ltd.
Phase 3
1,615
Shanghai, Tianjin
2023-11-20
Active, closed
Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)
NCT06300476Stargardt Disease 1
West China Hospital
Phase 1/2
9
Chengdu
2023-11-20
Recruiting
Safety, Tolerability, and Pharmacokinetic Characteristics of SSS11 in Patients With Gout and Hyperuricemia
NCT06629376Gout, Hyperuricemia
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 1
60
Shanghai
2023-11-20
Recruiting
Prediction of Hepatocellular Carcinoma Recurrence After Curative Treatment by Longitudinal Monitoring MRD Based on ctDNA
NCT06157060Hepatocellular Carcinoma Resectable
Zhujiang Hospital
Observational
255
Foshan, Guangzhou, Shaoguan
2023-11-20
Recruiting
Robot-assisted vs VATS for Thymoma
NCT06029621Thymoma
Shanghai Pulmonary Hospital, Shanghai, China
Not applicable
304
Shanghai, Zhejiang
2023-11-20
Recruiting
The Research Value of Multi-omics and Multi-modal Information in the Diagnosis and Treatment of Urinary System Tumors
NCT06490211Urinary System Carcinoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Observational
100
Wuhan
2023-11-20
Recruiting
Registration of Intravenous Thrombolysis for Acute Ischemic Stroke in Southwestern China๏ผˆIVTIS๏ผ‰
NCT06131385Stroke, Acute
Zhengzhou Yuan
Observational
3,000
Luzhou
2023-11-20
Recruiting
Safety and Efficacy of a Single Subretinal Injection of JWK002 Gene Therapy in Subjects With X-linked Retinoschisis(XLRS)
NCT06345898X Linked Retinoschisis
West China Hospital
Phase EARLY_PHASE1
12
Chengdu
2023-11-17
Active, closed
A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma
NCT05808608Renal Cell Carcinoma, First-line Treatment, Non Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma
Hao Zeng
Phase 1/2
37
Chengdu
2023-11-17
Recruiting
Efficacy and Safety of Dalpiciclib With Endocrine Therapy as Adjuvant Treatment in HR+/ HER2- Early Breast Cancer
NCT06341894Early Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
1,163
Nanjing
2023-11-17
Recruiting
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
NCT06123754Non-small Cell Lung Cancer
3D Medicines (Sichuan) Co., Ltd.
Phase 3
390
Tianjin
2023-11-17
Active, closed
Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor
NCT06057571Cholangiocarcinoma Metastatic
TransThera Sciences (Nanjing), Inc.
Phase 2
50
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou
2023-11-17
Recruiting
Evaluation of the Effect of Finerenone on Renal Function in Patients With Type 2 Diabetes and Chronic Kidney Disease
NCT06838416Type 2 Diabetes Mellitus, Chronic Kidney Disease, Renal Function
Second Affiliated Hospital of Soochow University
Observational
300
Suzhou
2023-11-17
Recruiting
A Study of SI-B003, BL-B01D1+SI-B003 and BL-B01D1+PD-1 Monoclonal Antibody in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
NCT06008054Esophageal Cancer, Gastric Cancer, Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
376
Beijing
2023-11-16
By invitation
Gut Microbiota and Metabolic Development in Early Childhood: A 3-Year Follow-Up Study
NCT07762729Gut Microbiota, Early Child Development
Children's Hospital of Fudan University
Observational
1,000
Yiyang, Nantong, Shanghai, Baoji, Quzhou
2023-11-16
Recruiting
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
Amgen
Phase 3
750
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Lanzhou, Guangzhou
2023-11-16
Recruiting
Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma
NCT06039735Multiple Myeloma
Qilu Hospital of Shandong University
Observational
50
Jinan
2023-11-16
Recruiting
Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of r/r DLBCL Clinical Research
NCT06120166Diffuse Large B-cell Lymphoma
He Huang
Phase EARLY_PHASE1
18
Hangzhou
2023-11-16
Recruiting
A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
NCT05692882Intracranial Arteriosclerosis, Stenosis Artery, Drug-Eluting Stents, Intracranial Artery Stenosis
Sino Medical Sciences Technology Inc.
Not applicable
1,000
Chenzhou, Ganzhou, Jinhua, Ningbo, Shanxi
2023-11-16
Recruiting
A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis ๏ผˆEGPA๏ผ‰
NCT05979051Eosinophilic Granulomatosis With Polyangiitis
Guangdong Hengrui Pharmaceutical Co., Ltd
Phase 2/3
166
Beijing, Hangzhou
2023-11-16
Recruiting
A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
NCT06697886Common Cold
Tasly Pharmaceutical Group Co., Ltd
Phase 3
480
Beijing, Changsha, Chengdu, Haerbin, Huizhou, Kaifeng, Luoyang, Luzhou
2023-11-16
Recruiting
Identification of Plasma Biomarkers for Early Diagnosis of Transplant-associated Thrombotic Microangiopathy
NCT06102694Thrombotic Microangiopathies, Hematopoietic Stem Cell Transplantation
Institute of Hematology & Blood Diseases Hospital, China
Observational
500
Tianjin
2023-11-16
Active, closed
Effects of Dapagliflozin on Progression of Alport Syndrome
NCT06226896Alport Syndrome
Nanjing University School of Medicine
Observational
222
Nanjing
2023-11-15
Active, closed
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.
NCT06063967Crohn's Disease
AbbVie
Phase 3
289
Chongqing, Xiamen, Guangzhou, Wuhan, Changsha, Changzhou, Nanjing, Wuxi
2023-11-15
Recruiting
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients With Gaucher Disease Type I
NCT06162338Gaucher Disease Type I
He Huang
Not applicable
3
Hanzhou
2023-11-15
Recruiting
A Prospective Birth Cohort of Infants With Allergy and Neurodevelopmental Disorders in China
NCT06327906Child Allergy, Neurodevelopmental Disorders
Qilu Hospital of Shandong University
Observational
6,000
Jinan
2023-11-15
Recruiting
A Study of the Zanubrutinib Given in Combination With Bendamustine and Rituximab in (Elderly or TP53 Alterations or Chemotherapy Intolerance) Patients With Newly Diagnosed Mantle Cell Lymphoma
NCT06136351Lymphoma, Mantle-Cell
Ruijin Hospital
Phase 2
23
Shanghai
2023-11-15
Recruiting
Single Arm, Prospective, Multicenter Clinical Study of TACE With Adebrelimab and Bevacizumab for Unresectable Hepatocellular Carcinoma
NCT05970666Adebrelimab, Hepatocellular Carcinoma, Transformation, Bevacizumab
The First Affiliated Hospital of Xiamen University
Phase 2
71
Xiamen
2023-11-15
Recruiting
Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer
NCT06359847Differentiated Thyroid Carcinoma
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 2
60
Beijing
2023-11-15
Active, closed
A Phase 3 Study Comparing TLL-018 to Tofacitinib in RA Subjects With Inadequate Response or Intolerance to bDMARDs
NCT06020144Rheumatoid Arthritis
Hangzhou Highlightll Pharmaceutical Co., Ltd
Phase 3
459
Beijing
2023-11-15
Recruiting
Gene Therapy for DME
NCT06492876Diabetic Macular Edema
Frontera Therapeutics
Phase 1/2
78
Tianjin
2023-11-15
Recruiting
Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)
NCT06095583Limited-stage Small Cell Lung Cancer (LS-SCLC)
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
756
Harbin, Changsha, Nanchang, Shenyang, Jinan, Anyang, Beijing, Changchun
2023-11-15
Active, closed
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
NCT06112379Breast Cancer
AstraZeneca
Phase 3
1,902
Beijing, Bengbu, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin
2023-11-14
Not yet open
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer
NCT05990127Locally Advanced or Metastatic NSCLC
Akeso
Phase 3
642
Bengbu, Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Zhangzhou, Lanzhou
2023-11-14
Recruiting
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
NCT06246162Multiple Myeloma
Affiliated Hospital of Nantong University
Phase 1/2
30
Nantong
2023-11-13
Recruiting
Cadonilimab Combination With Chemotherapy With or Without AK117 in Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05960955Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Akeso
Phase 2
90
Tianjin
2023-11-13
Recruiting
A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behรงet's Disease
NCT06145893Behรงet's Disease
Ganzhou Hemay Pharmaceutical Co., Ltd
Phase 3
162
Beijing, Xiamen, Guangzhou, Shenzhen, Guilin, Shijiazhuang, Xinxiang, Nanchang
2023-11-13
Recruiting
RecistTM Criteria in Evaluating the Efficacy of Targeted Therapy for NSCLC
NCT06142058Evaluation, NSCLC, Targeted Therapy
Xueqin Yang
Observational
44
Chongqing
2023-11-13
Active, closed
Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
NCT06124378Colonic Neoplasms, Neoadjuvant Therapy, Immune Checkpoint Inhibitors
First Affiliated Hospital of Guangxi Medical University
Phase 2
60
Nanning
2023-11-13
Active, closed
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast Cancer
NCT05870579Breast Cancer
Novartis Pharmaceuticals
Phase 1
28
Shanghai
2023-11-13
Recruiting
A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
NCT05319353Cytomegalovirus (CMV)
Takeda
Phase 3
80
Beijing, Guangzhou, Shenzhen, Shanghai, Tianjin
2023-11-13
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Phase 3
556
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Harbin
2023-11-12
Active, closed
Immunogenicity, Safety, and Antibody Persistence of Different Immunization Strategies Against Japanese Encephalitis
NCT06825312Japanese Encephalitis Vaccine
Liaoning Chengda Biotechnology CO., LTD
Phase 4
600
Jiaxing, Jinhua, Ningbo, Quzhou
2023-11-11
Recruiting
Fractional Flow Reserve Guided Immediate Versus Staged Complete Myocardial Revascularization in Patients With ST-segment Elevation Myocardial Infarction With Multivessel Disease (Future Study)
NCT05967663ST Elevation Myocardial Infarction
RenJi Hospital
Not applicable
840
Shanghai
2023-11-11
Recruiting
LCMS-Based Metabolic Analysis Explores the Effect of American Ginseng on Urine and Plasma in Healthy Individuals
NCT07252362The Impact of American Ginseng on the Metabolomics of Urine and Plasma in Healthy Individuals
Zhejiang Cancer Hospital
Not applicable
20
Hangzhou
2023-11-11
Active, closed
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
NCT06073821CLL
BeOne Medicines
Phase 3
652
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Jieyang, Nanning, Nanyang
2023-11-11
Active, closed
Comparative Study on AQP4 Antibody Detection Methods
NCT06767020NMOSD
First Affiliated Hospital of Chongqing Medical University
Observational
120
Chongqing
2023-11-11
Active, closed
Adjuvant Hypofractionation Radiotherapy for Thymic Epithelial Tumours After Complete Resection
NCT06189183Thymus Neoplasms
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
50
Beijing
2023-11-11
Recruiting
Combined Postoperative Radiotherapy With Kidney Sparing Surgery for Locally Advanced High-risk Ureteral Cancer
NCT06120387Locally Advanced, Urothelial Carcinoma Ureter
Xuesong Li
Observational
90
Beijing
2023-11-10
Not yet open
Safety and Efficacy Study of Implantable Neuromodulation for Poststroke Hemiplegia
NCT06121947Stroke Sequelae, Deep Brain Stimulation, Vagus Nerve Stimulation, Motor Recovery
Chinese PLA General Hospital
Not applicable
98
Beijing
2023-11-10
Active, closed
Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism
NCT06130683Secondary Hyperparathyroidism
China-Japan Friendship Hospital
Observational
12
Beijing
2023-11-10
Recruiting
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer
NCT06102772Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Recruiting
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
NCT06102785Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Recruiting
Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Advanced Gastric Cancer After PD-1 Antibody Failed
NCT06102759Gastric Cancer
Tianjin Medical University Cancer Institute and Hospital
Observational
30
Tianjin
2023-11-10
Recruiting
Safety and Efficacy of APRIL-BAFF-Bicephali CAR-T in Relapsed, Refractory Multiple Myeloma
NCT06132711Multiple Myeloma
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-11-10
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Extensive Stage Small Cell Lung Cancer
NCT05924841Small Cell Lung Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
100
Changchun
2023-11-10
Recruiting
Comparing Myopia Treatments in Youth: Defocus Spectacles, Glasses, and Ortho-K
NCT06278974Myopia, Cost-effectiveness Analysis, Quality of Life
He Eye Hospital
Observational
90
Shenyang
2023-11-10
Recruiting
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400
NCT06084481Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancers, Esophageal Squamous Cell Carcinoma
AbbVie
Phase 1
325
2023-11-09
Recruiting
Registration of Acute Ischemic Stroke With Large and Medium-sized Vascular Occlusion in Southwest China(LMVOS)
NCT06125236Acute Ischemic Stroke
Zhengzhou Yuan
Observational
8,000
Luzhou
2023-11-09
Active, closed
Evaluate the Safety, Tolerability of BAT6026
NCT06094179Dermatitis, Atopic
Bio-Thera Solutions
Phase 1/2
33
Beijing
2023-11-09
Recruiting
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
NCT05959356Metastatic Colorectal Cancer
Sun Yat-sen University
Phase 2
198
Foshan, Guangzhou, Guiyang
2023-11-09
Recruiting
Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis
NCT06503237Rheumatoid Arthritis
The First Affiliated Hospital of University of Science and Technology of China
Not applicable
18
Changsha
2023-11-09
Active, closed
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
NCT06097728Unresectable Pleural Mesothelioma
AstraZeneca
Phase 3
863
Beijing, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Kunming, Lanzhou
2023-11-09
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Beijing, Guangzhou, Hangzhou, Lanzhou, Shanghai, Tianjin
2023-11-08
Recruiting
Qishenyiqi Dripping Pill for Coronary Microvascular Disease
NCT06699420Coronary Microvascular Disease
Qilu Hospital of Shandong University
Phase 4
162
Jinan
2023-11-08
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Pfizer
Phase 3
1,571
Beijing, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Nanyang, Wuhan, Changsha
2023-11-08
Recruiting
A Phase Ib/II Study Confirmed Inhibition of Autophagy Synergizes Anti-tumor Effect of High Dose CDK4/6i
NCT05953350Inhibition of Autophagy Synergizes Anti-tumor Effect
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
29
Guangzhou
2023-11-07
Active, closed
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
NCT06122779Heart Failure
Bristol-Myers Squibb
Phase 2
227
Beijing, Guangzhou, Luoyang, Changsha, Hangzhou
2023-11-07
Recruiting
Personalized KSX01-TCRT in Patients With Advanced Solid Tumors
NCT06150365Refractory Solid Tumors, Relapsed Solid Tumors
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase EARLY_PHASE1
12
Beijing
2023-11-07
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
AstraZeneca
Phase 3
1,835
Baotou, Beijing, Changsha, Chengdu, Chongqing, Deyang, Foshan, Guangzhou
2023-11-07
Recruiting
A Study of ST-1898 for Unresectable or Metastatic Melanoma
NCT06359860Unresectable or Metastatic Melanoma
Beijing Scitech-Mq Pharmaceuticals Limited
Phase 1/2
64
Beijing
2023-11-07
Recruiting
Repetitive Transcranial Magnetic Stimulation Therapy in Essential Tremor
NCT06145932Essential Tremor
Second Affiliated Hospital of Soochow University
Not applicable
40
Suzhou
2023-11-07
Recruiting
Prospective Cohort of Patients With Intracerebral Hemorrhage
NCT06670456Stroke, Acute, Intracerebral Hemorrhage
De-zhi Kang
Observational
3,000
Fuzhou, Quanzhou, Xiamen, Zhangzhou, Liaocheng
2023-11-06
Recruiting
A Novel Ferumoxytol-enhanced Cardiac Magnetic Resonance Imaging for the Detection of Intracardiac Thrombus
NCT06146751Heart Aneurysm
The First Affiliated Hospital with Nanjing Medical University
Observational
320
Nanjing
2023-11-06
Recruiting
Safety and Efficacy of OCN19-overexpressed Human Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Refractory Type 2 Diabetes Mellitus
NCT06727721Diabetes, Type 2 Diabetes
Lu jin ๏ผŒMD
Phase 2
10
Shanghai
2023-11-06
Recruiting
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes๏ผˆCAR-T๏ผ‰ for CEA Positive Advanced Malignant Solid Tumors
NCT06126406Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer
Chongqing Precision Biotech Co., Ltd
Phase 1
60
Wuhu
2023-11-06
Recruiting
Catheter Ablation in Atrial Fibrillation Patients With HFpEF (STABLE-SR IV Trial)
NCT06125925Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction
The First Affiliated Hospital with Nanjing Medical University
Not applicable
436
Nanjing
2023-11-06
Recruiting
A Study of BL-B01D1, SI-B003 and BL-B01D1+SI-B003 in Patients With Recurrent or Metastatic Cervical Cancer and Other Gynecological Malignancies
NCT05990803Cervical Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 2
130
Beijing
2023-11-06
By invitation
Clinical Study of Rezvilutamide Combined With Docetaxel Chemotherapy in the Treatment of Abiraterone-Resistant Prostate Cancer
NCT07112209Pathological and Imaging Examinations Confirmed Metastatic Prostate Cancer
Zhujiang Hospital
Not applicable
20
Guangzhou
2023-11-06
By invitation
The Relation Between the Prognosis of Subthalamic Nucleus Deep Brain Stimulation Surgery by Microlesion Effect and Electrode Position
NCT06685510Parkinson&#39;s Disease (PD), Deep Brain Stimulation
Second Affiliated Hospital of Nanchang University
Observational
100
Nanchang
2023-11-06
Recruiting
Neoadjuvant Treatment For Locally Advanced Thymic Cancer
NCT06019468Thymic Carcinoma
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
25
Shanghai
2023-11-04
Recruiting
Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
NCT06078969Langerhans Cell Histiocytosis of Bone
Shanghai Changzheng Hospital
Phase 2
118
Shanghai
2023-11-04
Recruiting
Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)
NCT06125652Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
Xuzhou Medical University
Phase 1/2
20
Xuzhou
2023-11-04
Active, closed
Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL
NCT06093841Lymphoma, Large B-Cell, Diffuse, Follicular Lymphoma Grade 3B, High-grade B-cell Lymphoma, Mediastinal B-Cell Diffuse Large Cell Lymphoma
Shanghai Ming Ju Biotechnology Co., Ltd.
Phase 2
46
Guangzhou, Zhengzhou, Changsha, Suzhou, Jinan, Shanghai, Tianjin, Hangzhou
2023-11-03
Recruiting
A Study to Test Tetrandrine Tablets for Connective Tissue Disease-Related Lung Disease
NCT07319598Interstitial Lung Disease (ILD), Connective Tissue Disease-associated Interstitial Lung Disease
Peking University Third Hospital
Phase 4
100
Beijing
2023-11-02
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVOยฎ (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
Amgen
Phase 3
633
2023-11-02
Recruiting
Efficacy and Safety of Intravenous YOLT-201 for Transthyretin Amyloidosis Cardiomyopathy
NCT06082050Transthyroxin Amyloidosis Cardiomyopathy
Zhejiang University
Phase EARLY_PHASE1
7
Hangzhou
2023-11-02
Recruiting
Clinical Study of Oncolytic Virus in Glioblastoma
NCT07145047Glioblastoma (GBM)
Mianyang Central Hospital
Phase 1/2
20
Mianyang
2023-11-02
Recruiting
Disease Characteristics of IR-CAD: a Case-control Study
NCT06007248Coronary Artery Disease, Coronary Artery Stenosis, Coronary Artery Restenosis, Coronary Artery Disease Progression
Peking Union Medical College Hospital
Observational
30
Beijing
2023-11-02
Recruiting
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
NCT06008106Melanoma
Shanghai Kechow Pharma, Inc.
Phase 3
165
Beijing
2023-11-02
Recruiting
The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
NCT06503276Extranodal Marginal Zone B-cell Lymphoma
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase 2
50
Shanghai
2023-11-01
Recruiting
Cohort in Qianwan New District, Ningbo
NCT06387875Cardiovascular Diseases, Stroke, Non-Communicable Chronic Diseases
RenJi Hospital
Observational
30,000
Shanghai
2023-11-01
Recruiting
Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer
NCT06121570Breast Neoplasms
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1
24
Guangzhou
2023-11-01
By invitation
A Real-World Study of Biologic Therapy for Subclinical Psoriatic Arthritis
NCT06686082Subclinical Psoriatic Arthritis
Chao Ji
Observational
150
Fuzhou
2023-11-01
Rows per page Showing 14301–14400 of 19052
Previous 142 143 144 145 146 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site. Derived from ClinicalTrials.gov. Retrieved 23 September 2026. https://priyalifescience.com/clinical-trials-china?page=144

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →
→

Browse trials by condition

Breast Cancer (416) Advanced Solid Tumors (183) Gastric Cancer (183) Colorectal Cancer (179) Hepatocellular Carcinoma (161) Advanced Solid Tumor (159) Solid Tumor (145) Non-Small Cell Lung Cancer (144) Acute Ischemic Stroke (138) Lung Cancer (134) Pancreatic Cancer (132) Non-small Cell Lung Cancer (131) Multiple Myeloma (126) Coronary Artery Disease (111) Prostate Cancer (111)
→

Browse trials by site location

Beijing (5484) Shanghai (3827) Guangzhou (3318) Hangzhou (1812) Wuhan (1343) Chengdu (1291) Nanjing (1193) Changsha (1154) Chongqing (1056) Fuzhou (1018) Tianjin (940) Zhengzhou (921) Hefei (875) Jinan (785) Changchun (641)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.